Acute Myeloid Leukemia Classification

Leukemias are classified according to their acute and chronic progress as well as according to their lymphoid or myeloid cell origins. Acute myeloid leukemia is further classified into subtypes.

Most cancers and solid tumors are classified according to cell type, aggressiveness and propensity to spread to other organs. The classifications of AML however are based on the appearance of the cells and their genetic abnormality.

Classification systems

There are two major systems that are used to classify AML into subtypes. One of this is the French-American British (FAB) classification that was in use earlier and has been replaced by the newer World Health Organization (WHO) classification.

The French-American-British (FAB) classification

The French-American-British (FAB) classification of AML was developed in the 1970s by a group of French, American, and British leukemia experts.

They classified AMLs into subtypes from M0 to M7. This was based on the type of cell from which the leukemia developed and the level of maturity of the cells. The FAB classification relied on appearance of leukemia cells under the microscope after routine staining.

According to the FAB classification the subtypes M0 to M5 start in precursors of white blood cells. M6 AML originates in very early forms of red blood cells and M7 AML starts in early forms of cells that form platelets.

The FAB classification also defines symptom differences. For example, uncontrolled bleeding is seen in the M3 subtype of AML, also known as acute promyelocytic leukemia (APL).  The subtypes also predict prognosis and identify the best suitable treatment. APL for example is usually responsive to retinoids.

 

FAB subtype Name % of adult AML patients Prognosis compared to average for AML
M0 Undifferentiated acute myeloblastic 5% Worse
M1 Acute myeloblastic leukemia with minimal maturation 15% Average
M2 Acute myeloblastic leukemia with maturation 25% Better
M3 Acute promyelocytic leukemia (APL) 10% Best
M4 Acute myelomonocytic leukemia 20% Average
M4 eos Acute myelomonocytic leukemia with eosinophilia 5% Better
M5 Acute monocytic leukemia 10% Average
M6 Acute erythroid leukemia 5% Worse
M7 Acute megakaryoblastic leukemia 5% Worse

 


The World Health Organization (WHO) classification

The most used and more modern classification of AML is the World Health Organization (WHO) classification. The FAB classification system does not take into account several factors that may affect the outlook of the leukemia. Thus the WHO proposed a newer system that includes some of these factors to classify AML.

The WHO classification system divides AML into several broad groups. These include:-

  • AML with genetic abnormalities:-
    • AML with a translocation between chromosomes 8 and 21
    • AML with a translocation or inversion in chromosome 16
    • AML with changes in chromosome 11
    • APL (M3), which usually has translocation between chromosomes 15 and 17
  • AML with multilineage dysplasia meaning involvement of more than one abnormal myeloid cell type
  • AML related to previous chemotherapy or radiation
  • Unspecified AML including those that do not fall into one of the above groups. This includes:-
    • Undifferentiated AML (M0)
    • AML with minimal maturation (M1)
    • AML with maturation (M2)
    • Acute myelomonocytic leukemia (M4)
    • Acute monocytic leukemia (M5)
    • Acute erythroid leukemia (M6)
    • Acute megakaryoblastic leukemia (M7)
    • Acute basophilic leukemia
    • Acute panmyelosis with fibrosis
    • Myeloid sarcoma (also known as granulocytic sarcoma or chloroma)

Sometimes ALL with myeloid markers may be included under AML called AML with lymphoid markers, or mixed lineage leukemias or undifferentiated or biphenotypic acute leukemias (with both lymphocytic and myeloid features).

Further Reading

Last Updated: Jun 10, 2023

Dr. Ananya Mandal

Written by

Dr. Ananya Mandal

Dr. Ananya Mandal is a doctor by profession, lecturer by vocation and a medical writer by passion. She specialized in Clinical Pharmacology after her bachelor's (MBBS). For her, health communication is not just writing complicated reviews for professionals but making medical knowledge understandable and available to the general public as well.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Mandal, Ananya. (2023, June 10). Acute Myeloid Leukemia Classification. News-Medical. Retrieved on October 31, 2024 from https://www.news-medical.net/health/Acute-Myeloid-Leukemia-Classification.aspx.

  • MLA

    Mandal, Ananya. "Acute Myeloid Leukemia Classification". News-Medical. 31 October 2024. <https://www.news-medical.net/health/Acute-Myeloid-Leukemia-Classification.aspx>.

  • Chicago

    Mandal, Ananya. "Acute Myeloid Leukemia Classification". News-Medical. https://www.news-medical.net/health/Acute-Myeloid-Leukemia-Classification.aspx. (accessed October 31, 2024).

  • Harvard

    Mandal, Ananya. 2023. Acute Myeloid Leukemia Classification. News-Medical, viewed 31 October 2024, https://www.news-medical.net/health/Acute-Myeloid-Leukemia-Classification.aspx.

Comments

  1. Sudheer Buddy Sudheer Buddy India says:

    Maam, you saved my Life.
    Really,all my doubts are clear.

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
NIH launches precision medicine trial to test new treatments for myeloid cancers